Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Anti‐angiogenic therapy for lung cancer

Information

DOI:
https://doi.org/10.1002/14651858.CD008047Copy DOI
Database:
  1. Cochrane Database of Systematic Reviews
Version published:
  1. 07 October 2009see what's new
Type:
  1. Intervention
Stage:
  1. Protocol
Cochrane Editorial Group:

  1. Cochrane Lung Cancer Group

Copyright:
  1. Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Article metrics

Altmetric:

Cited by:

Cited 0 times via Crossref Cited-by Linking

Collapse

Authors

  • Nick Pavlakis

    Correspondence to: Department of Medical Oncology, Royal North Shore Hospital, St Leonards, Australia

    [email protected]

  • Gavin Marx

    Department of Medical Oncology, Royal North Shore Hospital, St Leonards, Australia

  • Shane White

    Oncology Unit, Austin Hospital, Victoria, Australia

  • Christopher W Lee

    BC Cancer Agency ‐ Fraser Valley Centre, Surrey, Canada

  • Mustafa Khasraw

    NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia

Contributions of authors

The senior and supervising reviewer is NP. He and MK will be involved in study selection, quality appraisal, data analysis and results discussion. Each of the other reviewers will be involved in selected quality appraisal and data extraction under specific subheadings listed in "types of interventions". All authors will be involved in assessment of the final review.

Declarations of interest

Dr Nick Pavlakis has served on Lung Advisory Boards for Amgen, Roche, Pfizer and Astra Zeneca; he has received speaking honoraria from Roche; he has received travel grants from Roche and Amgen.

Dr Chris Lee has received research Grant support from Astra Zeneca and served on Advisory Boards for Astra Zeneca and Bristol Myers Squibb.

Dr Gavin Marx has received Grant in Aid support from Progen Industries and Sanofi Aventis, and served on Advisory Boards for Astra Zeneca and Amgen. He has also received a speakers fee from Sanofi Aventis.

Dr Shane White has served on Advisory Boards for Astra Zeneca and Roche and received travel grants from Roche, Amgen and Astra Zeneca.

Dr Mustafa Khasraw has received travel grant and research funding support from Merck.

Acknowledgements

The Cochrane Lung Group is acknowledged for its valuable assistance.

Version history

Published

Title

Stage

Authors

Version

2009 Oct 07

Anti‐angiogenic therapy for lung cancer

Protocol

Nick Pavlakis, Gavin Marx, Shane White, Christopher W Lee, Mustafa Khasraw

https://doi.org/10.1002/14651858.CD008047